Oral Presentation at ASGCT
May 14, 2025, 7:30:00 PM UTC
Summary
Editas Medicine will present preclinical data on in vivo gene editing at the ASGCT Annual Meeting, focusing on innovative delivery methods and therapeutic strategies.
Company
EDITAS MEDICINE INC (EDIT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.editasmedicine.comSimilar Events
Presentation of In Vivo HSC Preclinical Data
Editas Medicine plans to present further in vivo HSC preclinical data by year-end 2025, showcasing advancements in gene editing.
clinical readoutEditas Medicine to present in vivo CRISPR liver target data at ASGCT 2025
Editas Medicine will present in vivo proof-of-concept data for a CRISPR-based gene editing approach targeting an undisclosed liver gene at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 14, 2025. The preclinical data, generated in mice and non-human primates, demonstrate significant upregulation of the target protein and reduction of a disease-associated biomarker using lipid nanoparticle (LNP) delivery of CRISPR/Cas RNA. The results support the development of a potential first-in-class therapy for a liver disease. Additional presentations on related gene editing strategies will also be made at the conference.
clinical readoutARCUS in vivo OTC, Large Gene Insertion (clinical stage partnered program)
Presentation on advances in genome editing technologies for large gene insertion at ASGCT.
clinical readoutASGCT 2025 Annual Meeting - Poster Presentation
Metagenomi will present three posters at the ASGCT 2025 Annual Meeting, showcasing advancements in genome editing technologies.
conference talk